메뉴 건너뛰기




Volumn 18, Issue 5, 2012, Pages 421-426

Chemotherapy alone for localized diffuse large B-cell lymphoma

Author keywords

involved field radiation therapy; Large B cell lymphoma

Indexed keywords

BLEOMYCIN; CYCLOPHOSPHAMIDE; CYTARABINE; DOXORUBICIN; ETOPOSIDE; FLUORODEOXYGLUCOSE F 18; IBRITUMOMAB TIUXETAN; IFOSFAMIDE; METHOTREXATE; PREDNISONE; RITUXIMAB; VINCRISTINE; VINDESINE;

EID: 84866948570     PISSN: 15289117     EISSN: 1540336X     Source Type: Journal    
DOI: 10.1097/PPO.0b013e31826c5907     Document Type: Review
Times cited : (23)

References (49)
  • 2
    • 77951010885 scopus 로고    scopus 로고
    • Aggressive lymphomas
    • Lenz G, Staudt LM. Aggressive lymphomas. N Engl J Med. 2010; 362:1417-1429.
    • (2011) N Engl J Med , vol.362 , pp. 1417-1429
    • Lenz, G.1    Staudt, L.M.2
  • 3
    • 47649096056 scopus 로고    scopus 로고
    • Gene expression differences between low and high stage diffuse large B cell lymphoma (DLBCL)
    • Abstract 809
    • Roberts RA, Rimsza LM, Staudt L, et al. Gene expression differences between low and high stage diffuse large B cell lymphoma (DLBCL). Blood. 2006;108:Abstract 809.
    • (2006) Blood , vol.108
    • Roberts, R.A.1    Rimsza, L.M.2    Staudt, L.3
  • 4
    • 77957200763 scopus 로고    scopus 로고
    • Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: A study by the Groupe d'Etudes des Lymphomes de l'Adulte
    • Coiffier B, Thieblemont C, Van Den Neste E, et al. Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte. Blood. 2010;116:2040-2045.
    • (2011) Blood , vol.116 , pp. 2040-2045
    • Coiffier, B.1    Thieblemont, C.2    Van Den Neste, E.3
  • 5
    • 0032474694 scopus 로고    scopus 로고
    • Chemotherapy alone compared with chemotherapy plus radiotherapy for localized intermediate- and high-grade non-Hodgkin's lymphoma
    • Miller TP, Dahlberg S, Cassady JR, et al. Chemotherapy alone compared with chemotherapy plus radiotherapy for localized intermediate- and high-grade non-Hodgkin's lymphoma. N Engl J Med. 1998;339:21-26.
    • (1998) N Engl J Med , vol.339 , pp. 21-26
    • Miller, T.P.1    Dahlberg, S.2    Cassady, J.R.3
  • 6
    • 0003242248 scopus 로고    scopus 로고
    • CHOP alone compared to CHOP plus radiotherapy for early stage aggressive non-Hodgkin's lymphomas: Update of the Southwest Oncology Group (SWOG) randomized trial
    • Miller TP, LeBlanc M, Spier C, et al. CHOP alone compared to CHOP plus radiotherapy for early stage aggressive non-Hodgkin's lymphomas: update of the Southwest Oncology Group (SWOG) randomized trial. Blood. 2001;98:724aY725a.
    • (2001) Blood , vol.98
    • Miller, T.P.1    Leblanc, M.2    Spier, C.3
  • 7
    • 0027444652 scopus 로고
    • A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project
    • Shipp MA, Harrington DP, Anderson JR, et al. A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. N Engl J Med. 1993;329:987-994.
    • (1993) N Engl J Med , vol.329 , pp. 987-994
    • Ma, S.1    Harrington, D.P.2    Anderson, J.R.3
  • 8
    • 77952477025 scopus 로고    scopus 로고
    • Standard International Prognostic Index remains a valid predictor of outcome for patients with aggressive CD20+ B-cell lymphoma in the rituximab era
    • Ziepert M, Hasenclever D, Kuhnt E, et al. Standard International Prognostic Index remains a valid predictor of outcome for patients with aggressive CD20+ B-cell lymphoma in the rituximab era. J Clin Oncol. 2010;28:2373-2380.
    • (2011) J Clin Oncol , vol.28 , pp. 2373-2380
    • Ziepert, M.1    Hasenclever, D.2    Kuhnt, E.3
  • 9
    • 0036137935 scopus 로고    scopus 로고
    • Brief chemotherapy and involvedregion irradiation for limited-stage diffuse large-cell lymphoma: An 18-year experience from the British Columbia Cancer Agency
    • Shenkier TN, Voss N, Fairey R, et al. Brief chemotherapy and involvedregion irradiation for limited-stage diffuse large-cell lymphoma: an 18-year experience from the British Columbia Cancer Agency. J Clin Oncol. 2002;20:197-204.
    • (2002) J Clin Oncol , vol.20 , pp. 197-204
    • Shenkier, T.N.1    Voss, N.2    Fairey, R.3
  • 10
    • 0037165261 scopus 로고    scopus 로고
    • CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma
    • Coiffier B, Lepage E, Briere J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med. 2002;346:235-242.
    • (2002) N Engl J Med , vol.346 , pp. 235-242
    • Coiffier, B.1    Lepage, E.2    Briere, J.3
  • 11
    • 33745982067 scopus 로고    scopus 로고
    • Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma
    • Habermann TM, Weller EA, Morrison VA, et al. Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma. J Clin Oncol. 2006;24:3121-3127.
    • (2006) J Clin Oncol , vol.24 , pp. 3121-3127
    • Habermann, T.M.1    Weller, E.A.2    Morrison, V.A.3
  • 12
    • 33646004738 scopus 로고    scopus 로고
    • CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: A randomised controlled trial by the MabThera International Trial (MInT) Group
    • Pfreundschuh M, Trumper L, Osterborg A, et al. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol. 2006;7:379-391.
    • (2006) Lancet Oncol , vol.7 , pp. 379-391
    • Pfreundschuh, M.1    Trumper, L.2    Osterborg, A.3
  • 13
    • 24644500086 scopus 로고    scopus 로고
    • Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British Columbia
    • Sehn LH, Donaldson J, Chhanabhai M, et al. Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British Columbia. J Clin Oncol. 2005; 23:5027-5033.
    • (2005) J Clin Oncol , vol.23 , pp. 5027-5033
    • Sehn, L.H.1    Donaldson, J.2    Chhanabhai, M.3
  • 14
    • 33744800503 scopus 로고    scopus 로고
    • Revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma (DLBCL) treated with rituximab and CHOP (R-CHOP)
    • Sehn LH, Chhanabhai M, Fitzgerald C, et al. Revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma (DLBCL) treated with rituximab and CHOP (R-CHOP). Blood. 2005;106:147a.
    • (2005) Blood , vol.106
    • Sehn, L.H.1    Chhanabhai, M.2    Fitzgerald, C.3
  • 15
    • 44249092120 scopus 로고    scopus 로고
    • Phase II study of rituximab plus three cycles of CHOP and involved-field radiotherapy for patients with limited-stage aggressive B-cell lymphoma: Southwest Oncology Group study 0014
    • Persky DO, Unger JM, Spier CM, et al. Phase II study of rituximab plus three cycles of CHOP and involved-field radiotherapy for patients with limited-stage aggressive B-cell lymphoma: Southwest Oncology Group study 0014. J Clin Oncol. 2008;26:2258-2263.
    • (2008) J Clin Oncol , vol.26 , pp. 2258-2263
    • Persky, D.O.1    Unger, J.M.2    Spier, C.M.3
  • 16
    • 0019840126 scopus 로고
    • Survival of patients with localized diffuse histiocytic lymphoma
    • Sweet DL, Kinzie J, Gaeke ME, et al. Survival of patients with localized diffuse histiocytic lymphoma. Blood. 1981;58:1218-1223.
    • (1981) Blood , vol.58 , pp. 1218-1223
    • Sweet, D.L.1    Kinzie, J.2    Gaeke, M.E.3
  • 17
    • 0021955804 scopus 로고
    • Long-termsurvival of patients with localized diffuse histiocytic lymphoma
    • Vokes EE, Ultmann JE, GolombHM, et al. Long-termsurvival of patients with localized diffuse histiocytic lymphoma. J Clin Oncol. 1985; 3:1309-1317.
    • (1985) J Clin Oncol , vol.3 , pp. 1309-1317
    • Vokes, E.E.1    Ultmann, J.E.2    Golomb, H.M.3
  • 18
    • 0023261426 scopus 로고
    • Brief chemotherapy and involved field radiation therapy for limited-stage, histologically aggressive lymphoma
    • Connors JM, Klimo P, Fairey RN, et al. Brief chemotherapy and involved field radiation therapy for limited-stage, histologically aggressive lymphoma. Ann Intern Med. 1987;107:25-30.
    • (1987) Ann Intern Med , vol.107 , pp. 25-30
    • Connors, J.M.1    Klimo, P.2    Fairey, R.N.3
  • 19
    • 0020619345 scopus 로고
    • A randomized study of radiotherapy versus radiotherapy plus chemotherapy in stage I-II non-Hodgkin's lymphomas
    • Nissen NI, Ersboll J, Hansen HS, et al. A randomized study of radiotherapy versus radiotherapy plus chemotherapy in stage I-II non-Hodgkin's lymphomas. Cancer. 1983;52:1-7.
    • (1983) Cancer , vol.52 , pp. 1-7
    • Nissen, N.I.1    Ersboll, J.2    Hansen, H.S.3
  • 20
    • 20144369743 scopus 로고    scopus 로고
    • ACVBP versusCHOP plus radiotherapy for localized aggressive lymphoma
    • Reyes F, Lepage E,GanemG, et al. ACVBP versusCHOP plus radiotherapy for localized aggressive lymphoma. N Engl J Med. 2005;352:1197-1205.
    • (2005) N Engl J Med , vol.352 , pp. 1197-1205
    • Reyes, F.1    Lepage, E.2    Ganem, G.3
  • 21
    • 4143102674 scopus 로고    scopus 로고
    • Chemotherapy with or without radiotherapy in limited-stage diffuse aggressive non-Hodgkin's lymphoma: Eastern Cooperative Oncology Group study 1484
    • Horning SJ,Weller E, Kim K, et al. Chemotherapy with or without radiotherapy in limited-stage diffuse aggressive non-Hodgkin's lymphoma: Eastern Cooperative Oncology Group study 1484. J Clin Oncol. 2004;22:3032-3038.
    • (2004) J Clin Oncol , vol.22 , pp. 3032-3038
    • Horning, S.J.1    Weller, E.2    Kim, K.3
  • 22
    • 33947543250 scopus 로고    scopus 로고
    • CHOP alone compared with CHOP plus radiotherapy for localized aggressive lymphoma in elderly patients: A study by the Groupe d'Etude des Lymphomes de l'Adulte
    • Bonnet C, Fillet G, Mounier N, et al. CHOP alone compared with CHOP plus radiotherapy for localized aggressive lymphoma in elderly patients: a study by the Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol. 2007;25:787-792.
    • (2007) J Clin Oncol , vol.25 , pp. 787-792
    • Bonnet, C.1    Fillet, G.2    Mounier, N.3
  • 23
    • 0033566341 scopus 로고    scopus 로고
    • Whole-body positron emission tomography using 18F-fluorodeoxyglucose for posttreatment evaluation in Hodgkin's disease and non-Hodgkin's lymphoma has higher diagnostic and prognostic value than classical computed tomography scan imaging
    • Jerusalem G, Beguin Y, Fassotte MF, et al. Whole-body positron emission tomography using 18F-fluorodeoxyglucose for posttreatment evaluation in Hodgkin's disease and non-Hodgkin's lymphoma has higher diagnostic and prognostic value than classical computed tomography scan imaging. Blood. 1999;94:429-433.
    • (1999) Blood , vol.94 , pp. 429-433
    • Jerusalem, G.1    Beguin, Y.2    Fassotte, M.F.3
  • 24
    • 77957940539 scopus 로고    scopus 로고
    • Benefit of consolidative radiation therapy in patients with diffuse large B-cell lymphoma treated with R-CHOP chemotherapy
    • Phan J, Mazloom A, Medeiros LJ, et al. Benefit of consolidative radiation therapy in patients with diffuse large B-cell lymphoma treated with R-CHOP chemotherapy. J Clin Oncol. 2010;28:4170-4176.
    • (2011) J Clin Oncol , vol.28 , pp. 4170-4176
    • Phan, J.1    Mazloom, A.2    Medeiros, L.J.3
  • 25
    • 80053384016 scopus 로고    scopus 로고
    • CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the MabThera International Trial (MInT) Group
    • Pfreundschuh M, Kuhnt E, Trumper L, et al. CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the MabThera International Trial (MInT) Group. Lancet Oncol. 2011;12:1013-1022.
    • (2011) Lancet Oncol , vol.12 , pp. 1013-1022
    • Pfreundschuh, M.1    Kuhnt, E.2    Trumper, L.3
  • 26
    • 69549152853 scopus 로고    scopus 로고
    • Effect of adding ibritumomab tiuxetan (Zevalin) radioimmunotherapy consolidation to three cycles of CHOP plus involved-field radiotherapy for limited-stage aggressive diffuse B-cell lymphoma (SWOG 0313)
    • abstract 3598
    • Miller TP, Unger JM, Spier C, et al. Effect of adding ibritumomab tiuxetan (Zevalin) radioimmunotherapy consolidation to three cycles of CHOP plus involved-field radiotherapy for limited-stage aggressive diffuse B-cell lymphoma (SWOG 0313). Blood. 2008;112:abstract 3598.
    • (2008) Blood , vol.112
    • Miller, T.P.1    Unger, J.M.2    Spier, C.3
  • 27
    • 80053555137 scopus 로고    scopus 로고
    • New strategies in diffuse large B-cell lymphoma: Translating findings from gene expression analyses into clinical practice
    • Friedberg JW. New strategies in diffuse large B-cell lymphoma: translating findings from gene expression analyses into clinical practice. Clin Cancer Res. 2011;17:6112-6117.
    • (2011) Clin Cancer Res , vol.17 , pp. 6112-6117
    • Friedberg, J.W.1
  • 28
    • 79551588807 scopus 로고    scopus 로고
    • Beyond chemotherapy: New agents for targeted treatment of lymphoma
    • Younes A. Beyond chemotherapy: new agents for targeted treatment of lymphoma. Nat Rev Clin Oncol. 2011;8:85-96.
    • (2011) Nat Rev Clin Oncol , vol.8 , pp. 85-96
    • Younes, A.1
  • 29
    • 0035281784 scopus 로고    scopus 로고
    • 2-(Fluorine-18)fluoro-2-deoxy- D-glucose positron emission tomography in the detection and staging of malignant lymphoma. A bicenter trial
    • Buchmann I, Reinhardt M, Elsner K, et al. 2-(Fluorine-18)fluoro-2-deoxy- D-glucose positron emission tomography in the detection and staging of malignant lymphoma. A bicenter trial. Cancer. 2001;91:889-899.
    • (2001) Cancer , vol.91 , pp. 889-899
    • Buchmann, I.1    Reinhardt, M.2    Elsner, K.3
  • 30
    • 79955833418 scopus 로고    scopus 로고
    • Role of functional imaging in the management of lymphoma
    • Cheson BD. Role of functional imaging in the management of lymphoma. J Clin Oncol. 2011;29:1844-1854.
    • (2011) J Clin Oncol , vol.29 , pp. 1844-1854
    • Cheson, B.D.1
  • 31
    • 0036124658 scopus 로고    scopus 로고
    • Fluorine-18 fluorodeoxyglucose positron emission tomography, gallium-67 scintigraphy, and conventional staging for Hodgkin's disease and non-Hodgkin's lymphoma
    • Wirth A, Seymour JF, Hicks RJ, et al. Fluorine-18 fluorodeoxyglucose positron emission tomography, gallium-67 scintigraphy, and conventional staging for Hodgkin's disease and non-Hodgkin's lymphoma. Am J Med. 2002;112:262-268.
    • (2002) Am J Med , vol.112 , pp. 262-268
    • Wirth, A.1    Seymour, J.F.2    Hicks, R.J.3
  • 32
    • 0035863387 scopus 로고    scopus 로고
    • Prognostic value of positron emission tomography (PET) with fluorine-18 fluorodeoxyglucose ([18F]FDG) after first-line chemotherapy in non- Hodgkin's lymphoma: Is [18F]FDG-PETa valid alternative to conventional diagnostic methods?
    • Spaepen K, Stroobants S, Dupont P, et al. Prognostic value of positron emission tomography (PET) with fluorine-18 fluorodeoxyglucose ([18F]FDG) after first-line chemotherapy in non- Hodgkin's lymphoma: is [18F]FDG-PETa valid alternative to conventional diagnostic methods? J Clin Oncol. 2001;19:414-419.
    • (2001) J Clin Oncol , vol.19 , pp. 414-419
    • Spaepen, K.1    Stroobants, S.2    Dupont, P.3
  • 33
    • 33947496614 scopus 로고    scopus 로고
    • Revised response criteria for malignant lymphoma
    • Cheson BD, Pfistner B, Juweid ME, et al. Revised response criteria for malignant lymphoma. J Clin Oncol. 2007;25:579-586.
    • (2007) J Clin Oncol , vol.25 , pp. 579-586
    • Cheson, B.D.1    Pfistner, B.2    Juweid, M.E.3
  • 34
    • 33947512956 scopus 로고    scopus 로고
    • Use of positron emission tomography for response assessment of lymphoma: Consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma
    • Juweid ME, Stroobants S, Hoekstra OS, et al. Use of positron emission tomography for response assessment of lymphoma: consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma. J Clin Oncol. 2007;25:571-578.
    • (2007) J Clin Oncol , vol.25 , pp. 571-578
    • Juweid, M.E.1    Stroobants, S.2    Hoekstra, O.S.3
  • 35
    • 64649093421 scopus 로고    scopus 로고
    • Fluorine-18-fluorodeoxyglucose positron emission tomography for interim response assessment of advanced-stage Hodgkin's lymphoma and diffuse large B-cell lymphoma: A systematic review
    • Terasawa T, Lau J, Bardet S, et al. Fluorine-18-fluorodeoxyglucose positron emission tomography for interim response assessment of advanced-stage Hodgkin's lymphoma and diffuse large B-cell lymphoma: a systematic review. J Clin Oncol. 2009;27:1906-1914.
    • (2009) J Clin Oncol , vol.27 , pp. 1906-1914
    • Terasawa, T.1    Lau, J.2    Bardet, S.3
  • 36
    • 84856799681 scopus 로고    scopus 로고
    • Treatment of limited stage DLBCL can be effectively tailored using a PET-based approach
    • abstract 028
    • Sehn LH, SavageKJ, Hoskins P, et al. Treatment of limited stage DLBCL can be effectively tailored using a PET-based approach. Ann Oncol. 2011;22:abstract 028.
    • (2011) Ann Oncol , vol.22
    • Sehn, L.H.1    Savagekj Hoskins, P.2
  • 37
    • 79960685420 scopus 로고    scopus 로고
    • How i treat primary CNS lymphoma
    • Ferreri AJ. How I treat primary CNS lymphoma. Blood. 2011;118:510-522.
    • (2011) Blood , vol.118 , pp. 510-522
    • Ferreri, A.J.1
  • 38
    • 79960239204 scopus 로고    scopus 로고
    • First-line treatment for primary testicular diffuse large B-cell lymphoma with rituximab-CHOP, CNS prophylaxis, and contralateral testis irradiation: Final results of an international phase II trial
    • Vitolo U, Chiappella A, Ferreri AJ, et al. First-line treatment for primary testicular diffuse large B-cell lymphoma with rituximab-CHOP, CNS prophylaxis, and contralateral testis irradiation: final results of an international phase II trial. J Clin Oncol. 2011;29:2766-2772.
    • (2011) J Clin Oncol , vol.29 , pp. 2766-2772
    • Vitolo, U.1    Chiappella, A.2    Ferreri, A.J.3
  • 39
    • 77956331404 scopus 로고    scopus 로고
    • Prognostic implications of extranodal involvement in patients with diffuse large B-cell lymphoma treated with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone
    • Hui D, Proctor B, Donaldson J, et al. Prognostic implications of extranodal involvement in patients with diffuse large B-cell lymphoma treated with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone. Leuk Lymphoma. 2010;51:1658-1667.
    • (2011) Leuk Lymphoma , vol.51 , pp. 1658-1667
    • Hui, D.1    Proctor, B.2    Donaldson, J.3
  • 40
    • 21044457512 scopus 로고    scopus 로고
    • Diffuse large B-cell lymphoma: Clinical and biological characterization and outcome according to the nodal or extranodal primary origin
    • Lopez-Guillermo A, Colomo L, Jimenez M, et al. Diffuse large B-cell lymphoma: clinical and biological characterization and outcome according to the nodal or extranodal primary origin. J Clin Oncol. 2005; 23:2797-2804.
    • (2005) J Clin Oncol , vol.23 , pp. 2797-2804
    • Lopez-Guillermo, A.1    Colomo, L.2    Jimenez, M.3
  • 41
    • 1642499119 scopus 로고    scopus 로고
    • Diffuse large B-cell lymphoma: Clinical implications of extranodal versus nodal presentationVa population-based study of 1575 cases
    • Moller MB, Pedersen NT, Christensen BE. Diffuse large B-cell lymphoma: clinical implications of extranodal versus nodal presentationVa population-based study of 1575 cases. Br J Haematol. 2004;124:151-159.
    • (2004) Br J Haematol , vol.124 , pp. 151-159
    • Moller, M.B.1    Pedersen, N.T.2    Christensen, B.E.3
  • 42
    • 77954103840 scopus 로고    scopus 로고
    • Clinico-biological characterization and outcome of primary nodal and extranodal diffuse large B-cell lymphoma in the rituximab era
    • Gutierrez-Garcia G, Colomo L, Villamor N, et al. Clinico-biological characterization and outcome of primary nodal and extranodal diffuse large B-cell lymphoma in the rituximab era. Leuk Lymphoma. 2010;51:1225-1232.
    • (2011) Leuk Lymphoma , vol.51 , pp. 1225-1232
    • Gutierrez-Garcia, G.1    Colomo, L.2    Villamor, N.3
  • 43
    • 4143066762 scopus 로고    scopus 로고
    • Non-Hodgkin lymphoma and Hodgkin disease: Coregistered FDG PET and CT at staging and restagingVdo we need contrast-enhanced CT?
    • Schaefer NG, Hany TF, Taverna C, et al. Non-Hodgkin lymphoma and Hodgkin disease: coregistered FDG PET and CT at staging and restagingVdo we need contrast-enhanced CT? Radiology. 2004; 232:823-829.
    • (2004) Radiology , vol.232 , pp. 823-829
    • Schaefer, N.G.1    Hany, T.F.2    Taverna, C.3
  • 44
    • 84857920618 scopus 로고    scopus 로고
    • Late effects in the era of modern therapy for Hodgkin lymphoma
    • Burns LJ, Mikhaell JR, Schwartz BS et al, eds Washington, DC: American Society of Hematology
    • Hodgson DC. Late effects in the era of modern therapy for Hodgkin lymphoma. In: Burns LJ, Mikhaell JR, Schwartz BS et al, eds. Hematology. Washington, DC: American Society of Hematology; 2011:323-329.
    • (2011) Hematology , pp. 323-329
    • Hodgson, D.C.1
  • 45
    • 23144457283 scopus 로고    scopus 로고
    • Second primary cancers among 109 000 cases of non-Hodgkin's lymphoma
    • Brennan P, Scelo G, Hemminki K, et al. Second primary cancers among 109 000 cases of non-Hodgkin's lymphoma. Br J Cancer. 2005;93:159-166.
    • (2005) Br J Cancer , vol.93 , pp. 159-166
    • Brennan, P.1    Scelo, G.2    Hemminki, K.3
  • 46
    • 42949157852 scopus 로고    scopus 로고
    • Risk of subsequent solid tumors after non-Hodgkin's lymphoma: Effect of diagnostic age and time since diagnosis
    • Hemminki K, Lenner P, Sundquist J, et al. Risk of subsequent solid tumors after non-Hodgkin's lymphoma: effect of diagnostic age and time since diagnosis. J Clin Oncol. 2008;26:1850-1857.
    • (2008) J Clin Oncol , vol.26 , pp. 1850-1857
    • Hemminki, K.1    Lenner, P.2    Sundquist, J.3
  • 47
    • 33645745882 scopus 로고    scopus 로고
    • Risk of second malignancy after non-Hodgkin's lymphoma: A British Cohort study
    • Mudie NY, Swerdlow AJ, Higgins CD, et al. Risk of second malignancy after non-Hodgkin's lymphoma: a British Cohort study. J Clin Oncol. 2006;24:1568-1574.
    • (2006) J Clin Oncol , vol.24 , pp. 1568-1574
    • Mudie, N.Y.1    Swerdlow, A.J.2    Higgins, C.D.3
  • 48
    • 33745311546 scopus 로고    scopus 로고
    • The risk of secondary malignancies over 30 years after the treatment of non-Hodgkin lymphoma
    • Tward JD, Wendland MM, Shrieve DC, et al. The risk of secondary malignancies over 30 years after the treatment of non-Hodgkin lymphoma. Cancer. 2006;107:108-115.
    • (2006) Cancer , vol.107 , pp. 108-115
    • Tward, J.D.1    Wendland, M.M.2    Shrieve, D.C.3
  • 49
    • 84865347010 scopus 로고    scopus 로고
    • Limited-stage diffuse large B-cell lymphoma treated with abbreviated systemic therapy and consolidation radiotherapy: Involved-field versus involved-node radiotherapy
    • Campbell BA, Connors JM, Gascoyne RD, et al. Limited-stage diffuse large B-cell lymphoma treated with abbreviated systemic therapy and consolidation radiotherapy: involved-field versus involved-node radiotherapy. Cancer. 2012;118:4156-4165.
    • (2012) Cancer , vol.118 , pp. 4156-4165
    • Campbell, B.A.1    Connors, J.M.2    Gascoyne, R.D.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.